Nabriva Therapeutics plc
NBRVF
$0.0001
$0.000.00%
OTC PK
| 06/30/2023 | 03/31/2023 | 12/31/2022 | 09/30/2022 | 06/30/2022 | |
|---|---|---|---|---|---|
| Net Income | -8.92% | 26.39% | -74.37% | -8.09% | 5.79% |
| Total Depreciation and Amortization | -76.62% | -73.08% | -70.93% | -54.88% | -61.69% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 4,309.04% | 7.90% | 272.64% | -25.42% | -85.41% |
| Change in Net Operating Assets | 314.11% | 131.42% | 194.40% | 233.07% | 73.05% |
| Cash from Operations | 103.92% | 64.60% | 73.44% | 53.34% | 29.80% |
| Capital Expenditure | 100.00% | 91.43% | -12.50% | -10,400.00% | -163.37% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 3.85% | -- | 150.00% | 0.00% | -4.00% |
| Cash from Investing | 56.90% | 91.67% | 41.67% | -- | -327.45% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 100.00% | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -84.48% | -49.79% | -96.94% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 100.00% | 102.27% | 86.82% | 65.55% | 29.54% |
| Cash from Financing | 100.00% | -321.15% | -130.82% | -72.79% | -103.14% |
| Foreign Exchange rate Adjustments | -183.55% | 12.80% | 117.24% | -1,157.14% | 137.91% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 102.42% | 23.49% | 48.59% | 41.01% | -318.90% |